| abstract |
This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumours and tumour metastases), particularly to the mediation of cytotoxicity of tumour cells evidencing surface expression of CD9, and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxms, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. |